Arcturus Therapeutics Holdings Inc.
NASDAQ:ARCTBiotechnology
+$0.15 today
- Market cap
- $231.73M
- Beta
- 2.35
- P/E (TTM)
- -2.7
- EPS (TTM)
- -$2.77
Volume 0.64M
Average 0.43M
ARCT Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
Arcturus Therapeutics Holdings Inc.NASDAQ: ARCT
Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Financing cash flow declines year over year
Q1 FY2026 financing cash flow of $16K fell 99.9% year over year, ahead of the -109.8% change in trailing-twelve-month financing cash flow. Sequentially, it fell 99.9% from the prior quarter.
Context
- Financing cash flow amounted to 19.9% of revenue in FY2025, up 16.0 pp from a year earlier.
- Financing cash flow increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -99.9% holds above the trailing-twelve-month pace of -109.8%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 13.38M USD
- Year-over-year change
- +147.0%
- 4-year CAGR
- -27.3%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 13.38M | +147.0% |
| FY2024 | 2024-12-31 | 5.42M | +122.5% |
| FY2023 | 2023-12-31 | (24.09M) | -742.5% |
| FY2022 | 2022-12-31 | (2.86M) | -106.0% |
| FY2021 | 2021-12-31 | 48.02M | — |
Financing Cash Flow vs competitors
How ARCT compares with its peers on the latest reported figures
- Peers report in different currencies, so financing cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -109.8% is the lowest of 10, against a peer median of -17.1%.
- Financing cash flow amounts to 4.0% of revenue for ARCT, versus a peer median of 12.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $165.71M USD | +3328.0% | -52.2% | 253.0% | |
| LTM Mar 2026 | $106.87M USD | -1.1% | — | — | |
| LTM Mar 2026 | $72.47M USD | -70.7% | -56.0% | 12.2% | |
| LTM Mar 2026 | $52.98M USD | -17.1% | -13.5% | — | |
| LTM Mar 2026 | €33.89M EUR | +4.1% | — | 21.7% | |
| LTM Mar 2026 | $25.14M USD | +10830.9% | — | — | |
| LTM Mar 2026 | $14.56M USD | -52.0% | -43.6% | 7.6% | |
| LTM Mar 2026 | $1.8M USD | -109.8% | — | 4.0% | |
| LTM Mar 2026 | €1.63M EUR | -102.3% | -61.5% | 12.2% | |
| LTM Mar 2026 | $155K USD | -99.9% | -90.2% | — | |
| LTM Mar 2026 | $911.01 USD | — | -93.4% | 0.1% | |
| Peer median (excluding ARCT) | — | -17.1% | -56.0% | 12.2% | |
Competitors are the stored peer set for ARCT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (203.67M) | 9.35M | (29.73M) | (80.94M) | (65.78M) |
| Depreciation & Amortization | 1.19M | 1.53M | 2.96M | 3.54M | 3.03M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 28.92M | 30.61M | 34.65M | 37.99M | 25.41M |
| Change in Working Capital | 32.63M | (12.56M) | 7.38M | (20.81M) | (39.2M) |
| Accounts Receivables | (1.24M) | 603K | (29.3M) | 28.09M | (1.59M) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (769K) | (3.11M) | (2.24M) | 1.92M | (2.96M) |
| Other Working Capital | 34.64M | (10.05M) | 38.92M | (50.81M) | (34.65M) |
| Other Non-Cash Items | 5.9M | 3.06M | (33.36M) | 471K | 2.28M |
| Operating Cash Flow | (135.04M) | 31.99M | (18.1M) | (59.75M) | (74.27M) |
| Capital Expenditures | (3.41M) | (7.73M) | (2.9M) | (648K) | (230K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (3.41M) | (7.73M) | (2.9M) | (648K) | (230K) |
| Debt Repayment | 46.6M | (5M) | (27.36M) | 0 | 0 |
| Common Stock Issued | 515K | 411K | 609K | 682K | 13.38M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 902K | 1.73M | 2.67M | 4.74M | 0 |
| Financing Cash Flow | 48.02M | (2.86M) | (24.09M) | 5.42M | 13.38M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (90.43M) | 21.41M | (45.09M) | (54.98M) | (61.12M) |
| Free Cash Flow | (138.45M) | 24.27M | (21M) | (60.4M) | (74.27M) |
Arcturus Therapeutics Holdings Inc.
NASDAQ:ARCT
Intrinsic Alpha fair value
Locked
Current Price
$8.04
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.